Intravenous Infusions is trading at GHS 0.50 (+8.70%), rebounding after recent declines.
- It rose from GHS 0.46 on August 17, 2026.
- No clear company-specific announcement explaining the August 19, 2026 movement was identified; available coverage mainly discusses the earlier profit turnaround and board appointment.
- Healthcare-sector strength offers supportive context, but broader markets were mixed, leaving the catalyst uncertain.